CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3)...
Transcript of CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3)...
![Page 1: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/1.jpg)
CDISC Europe Interchange 2019 - FDA Presentation
CDISC Interchange 2019
![Page 2: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/2.jpg)
Introduction and Overview
Lilliam Rosario, Ph.D.Director, Office of Computational Science
CDISC Interchange 2019
![Page 3: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/3.jpg)
3
Introduction
![Page 4: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/4.jpg)
4
Mission
![Page 5: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/5.jpg)
5
IND Application
![Page 6: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/6.jpg)
6
Phases of Clinical Testing
![Page 7: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/7.jpg)
7
The Review Process
![Page 8: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/8.jpg)
8
New Drug Application
![Page 9: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/9.jpg)
9
The Review Timeline
![Page 10: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/10.jpg)
10
Meet the Team
![Page 11: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/11.jpg)
The Impact of SEND on FDA Review of Nonclinical Study Data
CDISC Europe Interchange 2019
Matthew Whittaker, Ph.D.Nonclinical Reviewer
FDA Center for Drug Evaluation and Research, Office Of New DrugsSilver Spring, MD
May 9, 2019
![Page 12: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/12.jpg)
Disclaimer
This presentation reflects the views of the presenter and should not be construed to
represent FDA’s views or policies
![Page 13: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/13.jpg)
Outline• Overview of nonclinical review at FDA• Janus Nonclinical• Impact of SEND on nonclinical review• Ongoing and future development initiatives
![Page 14: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/14.jpg)
FDA: OND & OCS RelationshipOffice of Medical Products and
Tobacco
Center for Biologics Evaluation and Research
(CBER)
Center for Tobacco Products
Center for Drug Evaluation &
Research (CDER)
Center for Devices & Radiological Health
(CDRH)
Office of New Drugs (OND)
Review Divisions (by Indication)
Clinical reviewers (medical officers)Nonclinical reviewers (Pharm/Tox)
Office of Translational Sciences
Office of Computational Science (OCS)
Tools & training for review of study data
Define functionality requirements for review tools
![Page 15: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/15.jpg)
Typical FDA Review Team for IND/NDADiscipline Role Office
Regulatory project manager
Project management-communicate with sponsor
Office of New Drugs
Clinical Primary reviewer Office of New Drugs
Team Leader
Nonclinical Primary reviewer Office of New Drugs
Team Leader
Chemistry, Manufacturing & Controls (CMC)
Primary Reviewer Office of Pharmaceutical Quality
Team Leader
Clinical Pharmacology Primary Reviewer Office of Translational Sciences –Office of Clinical Pharmacology
Team Leader
Biostatistics Primary Reviewer Office of Translational Sciences –Office of Biostatistics
Team Leader
![Page 16: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/16.jpg)
Nonclinical Reviewers in OND
• 247 Reviewers• 17 review divisions • All are Ph.D.s
– Pharmacology (areas of research vary widely)– Toxicology
• Come from post-docs, academic research, or industry positions
![Page 17: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/17.jpg)
Nonclinical toxicology studies
• Objectives oDefine toxic effects of a drug that could
potentially be seen in humans
oDefine the doses/exposures at which these effects might be expected to occur
![Page 18: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/18.jpg)
Nonclinical studies in support of clinical development
PRE-CLINICAL (before drug is tested in humans)
CLINICAL(testing of drug in humans)
IND submitted
In vitro Pharmacology Genetic Toxicology Safety Pharmacology
o CNSo Cardiovascularo Respiratory
“IND-enabling” toxicology studieso Rat o Non-rodent (dog or monkey) o Dose animals up to the duration of
the proposed opening clinical study (i.e. 14-days or 28-days)
30 d safety review
NDA submitted
10-month review period
Approval
Chronic toxicology o 6 month rat o 9 month dog/monkey
Reproductive toxicology studies o Fertilityo Embryofetal
development
Carcinogenicity Pre & postnatal
development
IND Phase (several years)
![Page 19: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/19.jpg)
Major review principles
(1) Look for findings that show a dose-response relationship
(2) Of those findings, which ones are considered adverse?
• These 2 components are main factors in limit-dose determination
![Page 20: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/20.jpg)
Challenges with current approach to review of nonclinical studies
• Nonclinical study reports (NCSRs) submitted in pdf formato Data analysis requires re-typing of values from summary
tables into Excel o Variable formats used for organization of NCSRs - 1000+
page documents very difficult to navigateo Nonclinical study data is not readily searchable across
studies
• SEND datasets can address each of these issues
![Page 21: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/21.jpg)
Electronic study data regulations• FD&C Act Section 745A(a): Sponsors must use the data standards
defined in the FDA Data Standards Catalog starting 24-months after final guidance is issued for a specific submission type
Standard Application typeDates that standard is
acceptedDates that standard is
required*
SEND 3.0 NDA/BLA/ANDA 6/13/11 – 3/15/19 12/17/16
Commercial IND 6/13/11 – 3/15/20 12/17/17
SEND 3.1 NDA/BLA/ANDA 8/21/17 - 3/15/19
Commercial IND 8/21/17- 3/15/20
*Requirement dates refer to the nonclinical study initiation date (not the date that the study is submitted to the Agency)
![Page 22: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/22.jpg)
SEND studies submitted to FDA
# of SEND Studies (# of applications)
Application type Total* 2016 2017 2018
Commercial IND 369 (174) 3 (2) 47 (30) 319 (145)
NDA 54 (32) 8 (3) 8 (6) 38 (23)
BLA 3 (3) 0 1 (1) 2 (2)
*As of 12/28/18
• All SEND submissions to date have been in SEND 3.0
![Page 23: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/23.jpg)
Janus Nonclinical
![Page 24: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/24.jpg)
Janus Nonclinical
• FDA-specific, web-based application that allows users to analyze and visualize SEND datasets
• Pharm/tox reviewers from OND are guiding development of Janus NC by OCS
•Why?
![Page 25: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/25.jpg)
Janus Nonclinical• Current
o Table & figure format – consistent with general FDA reviewer practices
• Review documents – consistent formatting across reviewers & review divisions
• Ongoingo Interface with IND Smart Template
• Futureo Cross-study analysis (nonclinical)o Nonclinical – clinical data correlation
![Page 26: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/26.jpg)
Janus NC Dashboard• User assigns group alias, control group, set type in
the Study Sets Tableo 5 possible Set Types: interim, terminal, recovery,
toxicokinetic, satellite
![Page 27: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/27.jpg)
Janus NC Summary Table - BW
![Page 28: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/28.jpg)
Janus Nonclinical: Now• Janus NC summary tables reflect summary tables in NCSR
o Mean calculations based on Set Types defined in Dashboardo Highly customizable
• Dynamically filter & sort summary table datao Greatest impact: LB & MI
• Switch from Mean ± SD view to % change from control in 2 clickso Eliminates need for re-typing & analysis in Excel
• Individual animal data available from summary table (click on mean)
![Page 29: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/29.jpg)
Impact of SEND data on nonclinical review
![Page 30: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/30.jpg)
Current impact: Time Savings
Data table Traditional methods – pdf Janus NC
Clinical Chemistry 3+ hrs 30 – 45 mins
Histopathology 6 – 8 hrs 1 – 2 hrs
• Summary table preparation time
![Page 31: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/31.jpg)
Improved review efficiency: benefits
• More time to critically consider observed findings in tox studieso Risk assessment o Sponsor’s perspective & potential explanations for findings
• Potentially earlier engagement with sponsors on specific review issues (rather than at the last minute before the 30 d review clock is about to expire)
![Page 32: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/32.jpg)
Improved review efficiency: benefits• P/T Reviewers: 50+ INDs/NDAs/BLAs in their portfolio at
any given timeo Submissions are constantly coming in to each INDo P/T reviewers: Must keep up with new clinical protocols,
clinical protocol amendments, nonclinical inquiries, new study reports…
• Reality: Prioritize PDUFA deadline-related assignments
• More efficient review of tox studies more time to keep up with ongoing portfolioo More timely responses to inquiries with non-PDUFA
mandated timelines?
![Page 33: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/33.jpg)
Improved review efficiency: benefits
• More time to engage in non-review activities– Subcommittees within FDA
• Examine topics of scientific interest
– Engagement with industry/academic community
![Page 34: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/34.jpg)
Future impact
• More informed regulatory decision-makingo Janus: Warehouse of nonclinical datasets
• Robust historical control databases• Within a single product
o Follow specific findings across studies of different durations
oCompare specific findings across species
• Across productsoUnderstand effects of drug classes (i.e. products
targeting the same molecular pathway) on different nonclinical species
![Page 35: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/35.jpg)
OCS Support for Pharm/tox Reviewers
![Page 36: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/36.jpg)
Integrated approach• Tools
o For analysis and visualization of SEND data• Janus Nonclinical• Other commercially available software applications for specific uses
• Trainingo SEND standard (how nonclinical study data is modeled in SEND)o Practical use of Janus Nonclinicalo Formats: Videos, instructor-led seminars, text documents
• Resourceso KickStart Service
• Conducted at the request of pharm/tox reviewer• In-person seminar
Data quality assessment of SEND datasets Orient reviewer to how their SEND submissions are organized Instruction on use of Janus Nonclinical to identify key findings
o OCS Service Desk
![Page 37: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/37.jpg)
Ongoing & future development initiatives
• Training – for all nonclinical reviewers in ONDo SEND standard (how nonclinical study data is
modeled in SEND)o Practical use of Janus Nonclinical
• Janus Nonclinicalo Optimize summary table displays for all domainso Graphing/ data visualization enhancementso Cross-study analyses
![Page 38: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/38.jpg)
Summary
• Nonclinical reviewers in OND work closely with staff in OCS to guide development of Janus Nonclinical (FDA-specific software application for visualization/analysis of SEND data)
• Janus Nonclinical – increased review efficiencyo Much faster identification of treatment-related findings than
traditional methods with pdf NCSRs
• Increased review efficiency - expected to benefit both FDA and Sponsors
![Page 39: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/39.jpg)
A Clinical Reviewer’s Approach to the Evaluation and Interpretation of Structured Data
Alan M Shapiro, MD, PhD, FAAPHelena Sviglin, MPH
CDISC Interchange 2019
![Page 40: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/40.jpg)
40
Disclaimer
“This presentation reflects the views of the author and should not be construed to represent FDA’s views or policies.”
![Page 41: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/41.jpg)
41
Overview
• Part I – The life of the Clinical Reviewer– Alan Shapiro
• Part II – How OCS impacts review – Helena Sviglin
![Page 42: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/42.jpg)
42
Part I Overview
• Approach to safety evaluation 80 – 100% manual work
• Considerations for safety evaluation• Example of using safety matrix for a product
Safety Evaluation• Summary
![Page 43: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/43.jpg)
43
Integrative Safety Review
Safety review requires comprehensive integrative approach utilizing knowledge from product indication, product class and its development history along with the product’s safety findings
This information needs to be organized in a fashion to help reviewers integrate and make safety determinations
One approach is the ‘Safety Matrix’ which will be discussed in this presentation
![Page 44: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/44.jpg)
44
EVALUATION OF SAFETY RESULTS USING CLINICAL REVIEWER ASSEMBLED INFORMATION
![Page 45: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/45.jpg)
45
Pre-NDA or Pre-BLA Submission Information
45
1 Drugs and biologics can have primary and secondary targets
2Product or product class findings• Literature search• Labels search (e.g. FDALabel)• Post-marketing data from FAERS
3 Pre-clinical and IND phase (Phase 1 –Phase 3) findings• Includes all forms of data• Evaluation usually done with support from pharmacology-toxicology
reviewer• Initial IND submission with pre-clinical reports• Reports and other information from clinical IND phase
o Additional sources of Informationo Study investigational brochureo Development safety update Report (DSUR)
![Page 46: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/46.jpg)
46
Product Indication Information
Underlying disease safety related findings– Drug indication signs and symptoms
• Medical textual resources • Text mining tools are needed to summarize
this information
![Page 47: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/47.jpg)
47
NDA or BLA Submission Safety ComponentsInitial Overview
• Proposed product labeling• Clinical ‘Summary of Safety’• Tabular listing of clinical studies• Study by study Information
– Clinical study report (CSR) for each study and addendums
– Study data reviewer’s guide (SDRG)– Analysis data reviewer’s guide (ADRG)
![Page 48: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/48.jpg)
48
Tools Used for Adverse Event Analyses
• MedDRA Adverse Event Diagnosis (MAED)• MedDRA at a Glance• Internally developed scripts • Commercial tools that integrate and analyze multiple domains
Initial Evaluation of Safety Results
Comparative Clinical Trials Used for Analysis
• Product versus Placebo• Product versus comparison• Dose-safety analyses
![Page 49: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/49.jpg)
49
Considerations for Safety Analysis
Verify findings identified by the
Applicant
Identify product class issues not found so far for
the product
Design custom MedDRA queries to identify safety
signals
Identify new safety signal not
previously identified(not found in IND phase
or other products in class)
![Page 50: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/50.jpg)
50
Example of Safety Evaluation of a Hypothetical Product
• Therapeutic Monoclonal Used Against a Respiratory Viral Disease in Pediatric Patients administered sub-cutaneously
• Respiratory virus infection leads to fever, wheezing, apnea, morbilliform rash, diarrhea and occasionally pneumonia
• Humanized monoclonal antibody targets virus to block infectivity
• Even though monoclonal is humanized, there is a risk of hypersensitivity reactions to this protein product– Hypersensitivity can be manifested by various clinical findings
• Rash and angioedema• Respiratory difficulties or compromise in upper and lower airways• Alteration in liver laboratories
![Page 51: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/51.jpg)
51
Blood and lymphatic system disorders Leukocytosis Neutropenia NeutropeniaCardiac disorders TachycardiaGastrointestinal disorders DiarrhoeaGeneral Disorders and Administration Site Conditions Injection site reaction Injection site reactionHepatobiliary disorders and related Investigations Transaminases increased Transaminase increasedImmune system disorders PneumoniaInfections and infestations Hypersensitivity
Respiratory, thoracic and mediastinal disorders Wheezing, Apnoea Wheezing
Laryngospasm, Apparent life threatening event
Skin and subcutaneous tissue disorders Rash morbilliform urticaria urticaria
MedDRA SOC Disease FindingsProduct and Product Class Safety Issues
Product Safety AE Dataset Findings
Matrix for Evaluation of Safety in MedDRA Preferred Terms
Found in Class and Product safety
Found in Class and not in Product Safety
Found in Disease, Class, and Product Safety
![Page 52: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/52.jpg)
52
Findings from Safety Matrix
• Product class issues are also seen in the product under review yellow– Neutropenia– Injection site reaction– Transaminase increased– Urticaria
pink• Product class issue of hypersensitivity not found in product safety?– NO: findings of laryngospasm and urticaria are consistent
with hypersensitivity reaction• Need safety reviewer with clinical training to associate findings
![Page 53: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/53.jpg)
53
Summary – Part I
Safety review requires comprehensive integrative approach utilizing: knowledge of the indication product chemical and biological properties safety findings in the product class product development history safety findings from submitted datasets
Much of the safety evaluation is manual Clinical safety reviewer needs to be able to comprehensively
identify and characterize safety findings to include in product labeling
Requires clinical expertise and support from others on the review team
Review team needs better data and adequate analytic tools
![Page 54: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/54.jpg)
54
Part II - How does OCS help the Reviewer tackle the safety review?
• Develops review tools that help the Reviewer inquiry and manipulate the study data– MAED– CoreDF
• Provides clinical, review, and data standards expertise– JumpStart– KickStart– OCS Service Desk for additional consult– FDALabel
![Page 55: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/55.jpg)
55
MAED
• OCS developed tool to help reviewers look for potential signals in the tabular adverse event data
• MAED also works on legacy data• SMQ inquiry – broad and narrow• Provides some basic statistics (point estimates,
confidence intervals, etc.) for hypotheses generating
![Page 56: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/56.jpg)
56
MAED
![Page 57: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/57.jpg)
57
CoreDF - Overview
![Page 58: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/58.jpg)
58
CoreDF – Summary Report
![Page 59: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/59.jpg)
59
CoreDF - Coding Report
• Insert slide for CoreDF AE coding report here• Demo the coding report after Alan’s slide as part
of her presentation (CoreDF reports have been prepared for a study similar to the one Alan is talking about. The CoreDF report has been anonymized, but does not plan to release it as part of conference materials)
![Page 60: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/60.jpg)
60
CoreDF – Treatment Arm anamolies
![Page 61: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/61.jpg)
61
CoreDF – Missing Dates
![Page 62: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/62.jpg)
62
CoreDF – Supplemental Domain Contents
![Page 63: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/63.jpg)
63
Summary – Parts I and II
Safety review requires comprehensive integrative approach utilizing: knowledge of the indication product chemical and biological properties safety findings in the product class product development history safety findings from submitted datasets
Much of the safety evaluation is manual Clinical safety reviewer needs to be able to comprehensively
identify and characterize safety findings to include in product labeling
Requires clinical expertise and support from others on the review team
Review team needs better data and adequate analytic tools
CDISC and PhUSE
collaborations
OCS tools and services
![Page 64: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/64.jpg)
64
Additional Resources
• OCS public website• [email protected] (CDER)• [email protected] (CBER)• Study Data Standards Resources website• [email protected]
![Page 65: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/65.jpg)
A Statistical Reviewer’s Perspective on Data Review in NDA/BLA Submissions
Weiya Zhang, Ph.D.Statistical Reviewer, CDER/OTS/OB/DBIII
CDISC Europe InterChange, May 9, 2019
![Page 66: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/66.jpg)
Disclaimer
This presentation reflects the views of the speaker and should not be construed to represent FDA’s views or policies
![Page 67: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/67.jpg)
Outline
• Statistical reviewer’s perspective of NDA/BLA review
• Recommendations on NDA/BLA data submissions
![Page 68: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/68.jpg)
Study Data in Clinical Trials
Subjects from study
sitesCRFs SDTM ADaM CSR
TAUGs
• Annotation• Define.xml
• Define.xml• Software
programs
• Software programs
• Follow protocol and SAP
![Page 69: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/69.jpg)
Study Data in Clinical Trials
Subjects from study
sitesCRFs SDTM ADaM CSR
TAUGs
• Annotation• Define.xml
• Define.xml• Software
programs
• Software programs
• Follow protocol and SAP• Reproduce/verify study results• Support product labels?
![Page 70: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/70.jpg)
21st Century Review
https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/UCM218757.pdf
![Page 71: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/71.jpg)
Pre-NDA Communication on Study Data
Topics:
• Study datasets and data standards to be applied
• Software programs
• Study (analysis) data reviewer’s guide (sdrg/adrg)
• ISE/ISS pooling strategies
• …
Suggestions:
• Request pre-NDA meeting
• Understand study data well
• Follow FDA guidance on data submission, communications, etc.
• Be specific on your pre-NDA meeting questions
![Page 72: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/72.jpg)
Pre-NDA Communication on Dataset – Example
Sponsor’s question:
• We will submit study datasets following SDTM 1.3/SDTMIG 3.1.2 for phase 2 trials A1 and A2 and phase 3 pivotal trial A3 and associated define.xml.
• We will submit analysis datasets for the phase 3 pivotal trial A3 and the phase 2 trial A1 following ADaM 2.1/ADaMIG 1.0 as well as supporting data definition files (define.xml).
• We do not plan to submit separate analysis datasets for other clinical trials.
• Analysis datasets created by the multiple imputation procedure will not be submitted, instead the SAS code generating the datasets will be submitted.
• Does the FDA agree with this proposal regarding submitted datasets?
![Page 73: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/73.jpg)
Pre-NDA Communication on Dataset – Example
Review Division’s Responses:
• Your proposal to submit study datasets based on SDTM 1.3/SDTMIG 3.1.2 , is acceptable.
• Your proposal to submit analysis datasets based on ADaM 2.1/ADaMIG1.0, is acceptable.
• In addition to analysis datasets for the Phase 3 trial A3 and the Phase 2 trial A1, you should submit analysis datasets for the Phase 2 trial A2.
• Your proposal to submit the SAS code used to generate the Multiple Imputation datasets is acceptable. In addition, submit the SAS code used to analyze the primary and secondary endpoints using these imputed datasets.
![Page 74: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/74.jpg)
Pre-NDA Communication on Dataset – Example
Review Division’s Additional Comments:
• Each analysis dataset should include the treatment assignments, baseline assessments, and key demographic variables.
• The analysis datasets should include all variables needed for conducting all primary, secondary, and sensitivity analyses included in the study report.
• For endpoints that include imputations, both observed and imputed variables should be included and clearly identified.
• Provide sufficient comments, adequate bookmarks, and hyperlinks in the data define files.
![Page 75: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/75.jpg)
Filing Review
• Datasets
• Data structure (Legacy, SDTM, ADaM)
• Define files sufficiently detailed
• Analysis datasets are sufficiently structured
• Software programs
• Clinical study reports
![Page 76: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/76.jpg)
Filing Review – if Issues Identified
Actions:
• Send information requests (IRs) for clarification
• Can submission related issues be resolved before filing?
– Yes, issue filing letter– No,
o Extend PDUFA clocko Refuse to file
Suggestions:
• Discuss content and format during pre-NDA meeting
• Follow FDA guidance
• Well-prepared data package
• Closely work with your regulatory staff
• Be prompt on IRs
![Page 77: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/77.jpg)
Conduct Review
Check regulatory histories (in the IND stage)
• Protocol/SAP is in alignment with Division’s recommendations?
• Drug specific concerns on efficacy and safety?
• Any issues were identified during trial conduct?
![Page 78: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/78.jpg)
Conduct Review• Check data quality• Check blinding/unblinding procedures• Verify the randomization treatment assignments• Reproduce the primary analysis datasets, particularly the primary endpoint and major secondary
endpoint(s); reproduce study efficacy results – Follow protocol/SAP and do programming
– Data definition files
– sdrg/adrg
– Submitted software programs (analysis result metadata)
• Conduct additional analyses on inconsistent results or clinical concerns• Send IRs if needed
![Page 79: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/79.jpg)
Example – Keep Consistency from SAP to Analysis
Pre-specified in SAP:
• Efficacy population: all randomized subjects who received study medication and had at least one post-treatment efficacy assessment
• Efficacy endpoint: response rate (from Questionnaire X)
• Statistical analysis: logistic regression model with two baseline characteristics
![Page 80: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/80.jpg)
Example – Keep Consistency from SAP to Analysis
Placebo(N=95)
Drug(N=92)
# of responder (%) 46 (48.4) 58 (63.0)
Difference (%) 14.6
p-value 0.043
Sponsor’s Analysis
![Page 81: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/81.jpg)
Example – Keep Consistency from SAP to Analysis
Placebo(N=95)
Drug(N=92)
Placebo(N=95)
Drug(N=93)
# of responder (%) 46 (48.4) 58 (63.0) 46 (48.4) 58 (62.4)
Difference (%) 14.6 14.0
p-value 0.043 0.052
Sponsor’s Analysis Reviewer’s Analysis
![Page 82: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/82.jpg)
Example – Keep Consistency from SAP to Analysis
Placebo(N=95)
Drug(N=92)
Placebo(N=95)
Drug(N=93)
# of responder (%) 46 (48.4) 58 (63.0) 46 (48.4) 58 (62.4)
Difference (%) 14.6 14.0
p-value 0.043 0.052
Sponsor’s Analysis Reviewer’s Analysis
![Page 83: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/83.jpg)
Example – Keep Consistency from SAP to Analysis
Placebo(N=95)
Drug(N=92)
Placebo(N=95)
Drug(N=93)
# of responder (%) 46 (48.4) 58 (63.0) 46 (48.4) 58 (62.4)
Difference (%) 14.6 14.0
p-value 0.043 0.052
Sponsor’s Analysis Reviewer’s Analysis
![Page 84: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/84.jpg)
Example – Keep Consistency from SAP to Analysis
Placebo(N=95)
Drug(N=92)
Placebo(N=95)
Drug(N=93)
# of responder (%) 46 (48.4) 58 (63.0) 46 (48.4) 58 (62.4)
Difference (%) 14.6 14.0
p-value 0.043 0.052
Sponsor’s Analysis Reviewer’s Analysis
Question: Who is this subject? Included in the analysis or not?
![Page 85: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/85.jpg)
Example – Keep Consistency from SAP to Analysis
Reviewer’s findings• Used PROC COMPARE and identified this subject• Subject’s RESP = missing • Define file:
PARAMCD PARAM DerivationRESP Response = 0 (failure) if a failure in Q1 or Q2 in Questionnaire X;
= missing if there is no failure, but one of the questions is missing;= 1 (success) otherwise
![Page 86: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/86.jpg)
Example – Keep Consistency from SAP to Analysis
PARAMCD PARAM DerivationRESP Response = 0 (failure) if a failure in Q1 or Q2 in Questionnaire X;
= missing if there is no failure, but one of the questions is missing;= 1 (success) otherwise
Define file:
Subject Q1 Q2 RESPxxxx Missing Success
Subject’s data point (only one post-treatment efficacy assessment):
![Page 87: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/87.jpg)
Example – Keep Consistency from SAP to Analysis
PARAMCD PARAM DerivationRESP Response = 0 (failure) if a failure in Q1 or Q2 in Questionnaire X;
= missing if there is no failure, but one of the questions is missing;= 1 (success) otherwise
Define file:
Subject Q1 Q2 RESPxxxx Missing Success Missing
Subject’s data point (only one post-treatment efficacy assessment):
Question: This subject had only one post-treatment record for Q2, shall this subject be included in the efficacy population?
Efficacy population: all randomized subjects who received study medication and had at least one post-treatment efficacy assessment
![Page 88: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/88.jpg)
Example – Keep Consistency from SAP to Analysis
PARAMCD PARAM DerivationRESP Response = 0 (failure) if a failure in Q1 or Q2 in Questionnaire X;
= missing if there is no failure, but one of the questions is missing;= 1 (success) otherwise
Define file:
Subject Q1 Q2 RESPxxxx Missing Success Missing
Question: This subject had only one post-treatment record for Q2, shall this subject be included in the efficacy population? Yes.
Efficacy population: all randomized subjects who received study medication and had at least one post-treatment efficacy assessment
Subject’s data point (only one post-treatment efficacy assessment):
![Page 89: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/89.jpg)
Example – Keep Consistency from SAP to Analysis
Reviewer’s actions:
• Communicate the findings with the review team and the Sponsor
• Conduct additional sensitivity analyses to assess the robustness of the study results
![Page 90: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/90.jpg)
Moving Forward…
• Follow protocol/SAP to define variables
• Follow define files strictly in programming
• Keep consistency from protocol/SAP, define file, programming to analysis results
![Page 91: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/91.jpg)
My NDA/BLA Review Wishlist
• Clear datasets• Sufficient data definition files• Helpful sdrg/adrg (if provided)• Prompt responses to IRs• Close communication
![Page 92: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/92.jpg)
FDA Resource on Data Standards and NDA/BLA Review
![Page 93: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/93.jpg)
Reviewer’s Recommendation on Data Submissions
• Well-structured datasets and associated documentation
• Well-documented software programs
• Internal and external communication
• Follow FDA guidance• Be part of data standard development
![Page 94: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/94.jpg)
Reference
• FDA Study Data Standard Resources: https://www.fda.gov/industry/fda-resources-data-standards/study-data-standards-resources
• FDA Electronic Regulatory Submission and Review: https://www.fda.gov/drugs/forms-submission-requirements/electronic-regulatory-submission-and-review
• FDA: Best Practices for Communication Between IND Sponsors and FDA During Drug Development: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/best-practices-communication-between-ind-sponsors-and-fda-during-drug-development
• FDA: Guidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA Products• FDA: Guidance for Industry Providing Regulatory Submissions in Electronic Format — Standardized Study Data• FDA: Regulatory Submissions in Electronic Format — Submissions Under Section 745A(a) of the Federal Food, Drug,
and Cosmetic Act• FDA: Guidance for Industry Providing Regulatory Submissions in Electronic Format – Standardized Study Data
![Page 95: CDISC Europe Interchange 2019 - FDA Presentation · Pre-clinical and IND phase (Phase 1 –Phase 3) findings • Includes all forms of data • Evaluation usually done with support](https://reader030.fdocuments.net/reader030/viewer/2022040105/5e7cb42c957c795622453f00/html5/thumbnails/95.jpg)